Lab-On-A-Chip

Delivering Inter-Connectivity and Data Management.
Focused and Informed Analysis of Diagnostic Data
with Unmatched Specificity in Patient Test Results.

What Is Lab-On-A-Chip (LOC)?

Lab-On-A-Chip is a miniaturized device that integrates onto a single chip for several analyses, bringing solutions which are typically done in a large laboratory to a sophisticated Test Card. Delivering Unmatched analyses of RNA snapshots into DNA sequencing for In-Depth Biochemical Detection of Covid-19 and Providing Inflammation Insights in the Individual’s Whole Blood Profile.

Lab-On-A-Chip integrates laboratory processes within a few square centimeters. It uses a very small volume of samples to perform immediate reactions within the chip. The reactions vary from nucleic acid amplification and detection, to cell count and immunoassays; As a result, Microfluidic Diagnostics Test Cards perform a specific range of laboratory tests at a lower cost, and can benefit low-income settings and remote areas.

The revolutionary benefits of this Technology delivers a powerful tool to be used under the strict guidance of qualified physicians, researchers, and health institutions, to present a general assessment criteria for behavioral, symptomatic and other risk factors generated as a result of direct frequency of Point-of-Care and Laboratory Diagnostics. This routinized software system can map out specific standard-of-care pathways to help determine whether an individual should be quarantined-at-home or quarantined-in-care. LOC can assist organizations in deciding whether to isolate and treat, return-to-patient care, or whether to establish an un-impeded return-to-work flow for Frontline Healthcare Workers, Teams, Service Workers and the General Public.

This powerful system can flag suspicious bacteria and viruses to Healthcare Data Management Systems for specific medical review and/or informed clinical decision-making.

THE POST-PANDEMIC SOLUTION

Four-In-One Rapid Test System
Results in 4 Minutes!
100% Specificity

Scaled and Comprehensive Diagnostic Testing For Population Risk-Stratification

Detection and identification of acute and chronic infection, asymptomatic infection or immunized populations; depending on the time and phase of the infection, IgM, IgG antibodies can be used as early indicators for determining effective screening, observing the recovery process, and collecting data on groups who’ve been infected in the recent past. IgM is used to detect whether the body is in an acute infection state, and can also be used as an indicator for early diagnosis; IgG detection is critical in monitoring the patient’s disease progression and epidemiological screening of previous infections.

Ensuring Accuracy With SAA/CRP Testing In Clinical Applications

Most 2019-nCoV patients have elevated C-reactive protein CRP, indicating that CRP can be used to reflect the severity of the disease in infected patients and provide clinicians with first-hand diagnosis.

A patient’s Serum Amyloid A (SAA) will increase in both viral infections and bacterial infections. The difference is that during viral infections, SAA levels are generally between 10-100 mg/L, and bacterial infections often exceed 100 mg/L. Clinically, it is recommended to combine with CRP to diagnose infections, which can further improve the accuracy of identifying infections.

Why Serology Tests Are Superior To Single Nucleic Acid Tests (PCR)

A significant portion of patients who otherwise fit the diagnosis based on clinical and chest CT findings, including many hospitalized patients, have tested negative for viral RNA. Other common respiratory etiologies, such as influenza, were excluded. These remain “suspected” cases and may be reflective of false negativity in sampling. In some patients, the Covid-19 virus may be present in the lower respiratory secretion but absent in the upper respiratory tracts. Single Nucleic Acid Tests May Result In Misdiagnosis Of Asymptomatic Patients.